Recently added

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

ghiringhelli, francois; lawrence, yaacov; FELIP, ENRIQUETA; Zer, Alona; Greillier, Laurent; greystoke, alastair; Pardo Aranda, Nuria (BMJ, 2025-08)

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study

Kesselheim, Aaron; Tibau Martorell, Ariadna; Cliff, Edward; Romano Cardozo, Alejandra; Borrell, Maria; Molto Valiente, Consolacion (Elsevier, 2025-06)

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study

Roncaglia, Eleonora; GAFFO, Enrico; Calabretto, Giulia; Fürstenau, Moritz; Rogers, Kerry; Baliakas, Panagiotis; Abrisqueta, Pau (BMC, 2025-07-22)

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

Demeestere, Isabelle; Niman, Samuel; Partridge, Ann; Diego, Daniela S.; Kammler, Roswitha; Ruggeri, Monica; Saura Manich, Cristina (Elsevier, 2025-10)

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial

Chu, Quincy; AGGARWAL, CHARU; Majem Tarruella, Margarita; Barlesi, Fabrice; carcereny, Enric; MARTINEZ-MARTI, ALEX (American Medical Association, 2025-07)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Institut Català de la Salut - ICS: Recent submissions

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Institut Català de la Salut - ICS: Recent submissions

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study ﻿

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study ﻿

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study ﻿

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial ﻿

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial ﻿

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial